Available in English and Spanish, this e-newsletter separates fact from fiction on over 40 heart topics by Texas Heart Medical Group's Dr. Stephanie Coulter.
Texas Heart Institute (THI) conducts research through clinical trials as part of our mission to improve heart health. The trials conducted at THI are designed to test the safety and effectiveness of innovative new treatments and medications for patients.
Innovative Technologies & Techniques is produced at THI and explores promising advances in medicine that aim to extend the life of cardiac patients and patients at risk for series heart and vascular conditions. In response to the evolving pandemic, emerging topics related to COVID-19 are featured in the special Cardiology in the Time of COVID-19 episodes.
Our progress would not be possible without our donor community. Help support our mission by giving today.
Over the past six decades, physicians and scientists at the Texas Heart Institute have worked diligently with colleagues around the...
This #GivingTuesday, Texas Heart Institute will join millions around the world to inspire generosity by illuminating its commitment to protecting...
Diabetes is a major risk factor for heart disease—in fact, two-thirds of people with diabetes die of some form of...
Texas Heart Institute director of Regenerative Medicine Research and director of the Center for Cell and Organ Biotechnology, Dr. Doris A....
Texas Heart Institute Wellness hosted the first annual Fall Festival on October 24th in the Ansary Atrium. It was a...
THI celebrated the retirement of the Center for Clinical Research member, Juliette Dean, after 40 Years of outstanding service and commitment...
On Saturday, September 28, the Center for Women’s Heart and Vascular Health participated in the Holy Ghost Catholic Church Health Fair....
Dr. Bud Frazier will open Season 15 of Movies Houstonians Love at the Museum of Fine Arts Houston (MFAH) on Sunday,...
The Annual THI Perfusion Conference will be held June 7-9, 2019 at the Texas Heart Institute. The agenda for this...
